Media

Strongbridge Biopharma Investor and Analyst Day – Save the Date

Approval to launch the Phase I Study of repeated and increasing doses to assess CER-209 in NASH/NAFLD

NEXSTIM PLC PUBLISHES 2017 ANNUAL REPORT

Strongbridge Biopharma plc to Present at the Cowen and Company 38th Annual Healthcare Conference and the Oppenheimer 28th Annual Healthcare Conference

Wilson Therapeutics to Present at Upcoming Investor Conferences

Strongbridge Biopharma plc to Present KEVEYIS® (dichlorphenamide) Primary Periodic Paralysis Data at the 2018 American Academy of Neurology Annual Meeting

Nexstim Financial Statements Release 2017

Nordic Nanovector ASA – Results for the Fourth Quarter and Full Year 2017: Solid performance through 2017, moving forward with pivotal trial

Wilson Therapeutics AB (Publ) Year-End Report 2017

BONESUPPORT™ HOLDING AB (Publ) – Q4 and 2017 Year-End Report – January – December